UroGen Pharma reported third quarter 2026 sales of US$89 million with a sharply reduced net loss of US$1.46 million, and year to date sales of US$212.42 million with a smaller loss of US$39.39 million. The combination of stronger reported sales and a significantly lower basic and diluted loss per share indicates that UroGen Pharma’s cost base and commercial execution are starting to better align. The following section examines how UroGen Pharma’s sharply narrowed quarterly net loss could...
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be UroGen Pharma (URGN).
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...
UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics in targeted tissue sites for extended periods, the company addresses the significant clinical limitations of systemic toxicity and rapid clearance common in traditional cancer treatments. Its underlying […]
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) f
PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September. Wells Fargo 21st Annual Healthcare Conference Date / Time:September 9th, at 3:00 PM ETFormat:Fireside ChatLocation:Boston, MAWebcast Link:Here Cantor Global Healthcare Conference 2026 Date / T
Mark Schoenberg, Chief Medical Officer, on August 20, 2026, sold 60,677 shares in Urogen Pharma (URG
The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This is the newest page. Registered accounts read further back.